

CORRECTION

Correction: The cytotoxic, genotoxic and apoptotic effects of an adsorbent and anti oxidative vaginal gel on human cervical cancer cell (HeLa) lines

Gurkan Kiran¹, Eray Metin Guler^{2,3}, Abdurrahim Kocyigit⁴,
Ayse Filiz Gokmen Karasu^{1,*}, Norda Uckardes Katarmiyan¹,
Fatma Basak Tanoglu¹

¹Department of Obstetrics and Gynecology, Bezmialem University Faculty of Medicine, 34093 Istanbul, Turkey

²Department of Medical Biochemistry, Hamidiye School of Medicine, University of Health Sciences Turkey, 34668 Istanbul, Turkey

³Department of Medical Biochemistry, Hamidiye Faculty of Medicine, Haydarpasa Numune Health Application and Research Center, University of Health Sciences, 34668 Istanbul, Turkey

⁴Department of Biochemistry, Bezmialem University Faculty of Medicine, 34093 Istanbul, Turkey

*Correspondence

agokmenkarasu@bezmialem.edu.tr (Ayse Filiz Gokmen Karasu)

In the article [1] “The cytotoxic, genotoxic and apoptotic effects of an adsorbent and anti-oxidative vaginal gel on human cervical cancer cell (HeLa) lines” (Eur J Gynaecol Oncol, 2024; 45(4): 65–70), an error appeared in Section 2.2, first sentence.

The original sentence read:

“The cytotoxic activity of melatonin on cells was examined by measuring ATP (Adenosine triphosphate) levels using a luminescence test (Cell-Titer-Glo Luminescent Cell Viability Assay, Promega).”

The sentence should correctly read as follows:

“The cytotoxic activity of DeflaGyn® vaginal gel on cells was examined by measuring ATP levels using a lumines-

cence assay (Cell-Titer-Glo Luminescent Cell Viability Assay, Promega).”

This is a textual error limited to the first sentence of the Materials and Methods section. The experimental procedures, study design, data analyses, results, and conclusions of the study remain unchanged and are not affected by this correction.

REFERENCES

- [1] Kiran G, Guler EM, Kocyigit A, Karasu AFG, Katarmiyan NU, Tanoglu FB. The cytotoxic, genotoxic and apoptotic effects of an adsorbent and anti oxidative vaginal gel on human cervical cancer cell (HeLa) lines. European Journal of Gynaecological Oncology. 2024; 45: 65–70.